healthcare · ₹110 – ₹118 · —
Pramodini Medicare Limited is a diagnostic service provider in India, offering technology-enabled radiology, clinical laboratory, and nuclear medicine services. The company operates across public hospitals, private hospitals, PSUs, and standalone centers in Tier I, II, and III cities across India. It operates in the healthcare industry. The company was founded in 2000 and is based in Vijayawada, Andhra Pradesh, India.
The company earns revenue by providing diagnostic and related healthcare services. Revenue is recognized when diagnostic tests are conducted and reports are delivered to patients or customers, and it is measured at the fair value of the consideration received, net of discounts, rebates, and taxes. Its main products and services include Radiology (MRI, CT scan, X-ray, Ultrasound, Mammography, Dexa Scan, Intervention Radiology), Clinical Laboratory (Haematology, Micro-Biology, Immunology, Pathology & Bio-Chemistry), Nuclear Medicine (PET-CT, SPECT, Nuclear therapy) and Teleradiology services.
In its offer document the company lists its strengths as Strategic presence across various states of India, enabling wide reach and market penetration, Diversified business models (PPP, Private, PSU, Standalone) strengthening network and revenue stability and IT infrastructure and technical capability, ensuring efficient and scalable diagnostic services.
These open the registrar's and the exchanges' own websites. Pramodini Medicare Limited is not affiliated with CAPITA1, and we never ask for your PAN or application number.
“Broker Consensus” is CAPITA1's algorithmic verdict from GMP, subscription, fundamentals & valuation — broker recommendations aren't in our data feed. GMP is an unofficial grey-market estimate. Not investment advice.
Curated by CAPITA1 · Updated 5 Sept 2026 by CAPITA1 desk (composed from filing)
For educational purposes only. Not investment advice.
Company financials (EPS, NAV, ratios) from Issuer DRHP figures, compiled from public IPO listings. Ratios computed at the upper price band; not investment advice.
Generate an AI read of the offer document — business, risks, promoters, use of funds and an educational verdict, with citations back into the filing.
CAPITA1 desk — unofficial grey-market estimate — No exchange publishes a grey-market premium; this is not investment advice. Updated 11 Aug 2026, 08:49 am.
Subscription figures are not available for this issue.
As stated in the issue information filed with NSE.
Not Available
Market data: NSE (official calendar, issue filing and subscription) · CAPITA1 desk (GMP) · updated 20 Sept 2026, 01:38 pm
Fundamentals: Issuer DRHP figures, compiled from public IPO listings · fetched 14 Sept 2026, 03:57 pm
Corrected by CAPITA1: Sector · 05 Sept 2026, 12:54 pm
IPO calendar, issue details and subscription from NSE. Any grey-market premium shown is CAPITA1’s own unofficial estimate, collected daily from grey-market sources — not investment advice, and no exchange publishes one. Company fundamentals (financials, peers) are not part of the live feed.